Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride is a factor Xa specific chromogenic substrate.

S-2403 is a chromogenic substrate for plasmin and streptokinase-activated plasminoge

The activated factor X (FXa)-specific chromogenic substrate S-2732 is a short peptide covalently bound to pNA (4-nitroaniline). A free pNA will be cleaved off the peptide chain by activated factor X, thus enabling quantitive detection by a spectrophotometer.

Suc-YVAD-pNA is a colorimetric substrate for caspase-1/interleukin-1β-converting enzyme (ICE) and caspase-4.

Suc-AAP-Abu-pNA is a chromogenic peptide substrate for pancreatic elastase.It is cleaved by elastase to release p-nitroalinide (p-NA), which can be quantified by colorimetric detection at 405 nm as a measure of enzyme activity.

H-D-Phe-Pip-Arg-pNA (S-2238) dihydrochloride, a chromogenic substrate, is patterned after the N-terminal portion of the A alpha chain of fibrinogen, which is the natural substrate of thrombin. H-D-Phe-Pip-Arg-pNA dihydrochloride is specific for thrombin and is used to measure antithrombin-heparin cofactor (AT-III). The AT-III assay using H-D-Phe-Pip-Arg-pNA dihydrochloride is sensitive, accurate, and easy to perform.

The synthetic peptide Suc-Gly-Gly-Phe-pNA serves as a specific substrate for the enzyme chymotrypsin, demonstrating a Michaelis constant (Km) of 1.6 mM. This value reflects the substrate concentration at which the enzyme achieves half of its maximum reaction rate, indicating its affinity for the peptide.

Chromogenic peptide substrate for the determination of thrombin and antithrombin III

H-Gly-Arg-pNA is a colorimetric substrate for thrombin.

S2366 HCl is a chromogenic substrate for Factor XI in plasma.

CH3OCO-D-CHA-Gly-Arg-pNA acetate is a chromogenic substrate for factor Xa.

Ac-LEHD-pNA is a biological active peptide. (Caspase-9 substrate; pNA (4-nitroaniline)-derived caspase substrates are widely used for the colorimetric detection of various caspase activities. Cleavage of pNA peptides by caspases generates pNA that is monitored colorimetrically at ~405 nm. pNA has maximum absorption around 408 nm.)

Bz-IEGR-pNA is a colorimetric substrate for Factor Xa.

S-2302 is a Chromogenic substrate for plasma kallikrein, factor XIa and factor XIIa.

ARV-393 is an orally active PROTAC that utilizes the ubiquitin-proteasome system to target the degradation of BCL6. ARV-393 consists of ligand conjugates targeting BCL6 and the E3 ligase cereblon, respectively. ARV-393 has DC50 and GI50 values of <1 nM in multiple cell lines of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ARV-393 also demonstrated considerable tumor suppressor activity in tumor xenograft models. ARV-393 is being studied to inhibit non-Hodgkin lymphoma.

SY-5609 (CDK7-IN-3) is a selective CDK7 inhibitor with a KD of 0.059 nM. CDK7-IN-3 shows poor inhibition on CDK2 (Ki=390 nM), CDK9 (Ki=290 nM), CDK12 (Ki=78 nM). CDK7-IN-3 induce apoptosis in tumor cells and has antitumor activity.

2-Deoxy-2-fluoro-L-fucose, an L-fucose analog, is a fucosylation inhibitor. 2-Deoxy-2-fluoro-L-fucose inhibits de novo synthesis of GDP-fucose in mammalian cells. Fucosylation is a relatively well-defined biomarker for progression in many human cancers; for example, pancreatic and hepatocellular carcinoma.

Tiafenacil is a new protoporphyrinogen IX oxidase (PPO)-inhibiting herbicide, with IC50 values of 22 to 28 nM for various plant species, including amaranth (Amaranthus tuberculatus), soybean (Glycine max), arabidopsis (Arabidopsis thaliana), and rapeseed (Brassica napus).

DSPE-PEG(2000)-Amine is used in the synthesis of solid lipid and thermosensitive liposomal nanoparticles for the delivery of anticancer agents.

mPEG2000-DSPE is used in COVID 19 mRNA vaccines. It is a PEGylated derivative of 1,2-distearoyl-sn-glycero-3-PE . Formulations containing DSPE-MPEG(2000) have been used to prepare liposomes with long circulation time for the delivery of anticancer and antimalarial agents.. mPEG2000-DSPE has also been widely used as hydrophilic surface modifying agent for a variety types of hydrophobic nanoparticles, including recently reported lipid nanoparticle mRNA vaccines.

DSPE-PEG2000-OH is used for creating micelles that are able to carry drugs with low solubility.

DMPE-PEG, a synthetic lipid, possesses unique properties and finds extensive applications as liposomes. Firstly, DMPE-PEG exhibits excellent biocompatibility and solubility, allowing for its stable presence and efficient absorption and metabolism in vivo. Additionally, DMPE-PEG possesses good surface activity, aiding in the stabilization of liposome structures and enhancing their stability.

DOPE-PEG is a versatile phospholipid derivative with unique properties that make it suitable for various applications. Its hydrophobic and hydrophilic nature enables efficient encapsulation and delivery of drugs and nucleic acids, making it a valuable tool in drug delivery systems and gene therapy. Additionally, DOPE-PEG can enhance the stability and circulation time of liposomes, improving their efficacy as drug carriers.

LY3202626 is a small molecule non-selective BACE1 inhibitor, causes dose-dependent reductions in CSF and plasma Aβ concentrations, shows potential for the treatment of Alzheimer's disease..

Nalfurafine (TRK-820, TRK820) is potent, selective agonist of kappa-opioid receptor with Ki of 3.5 nM, 15-fold less potent for μOR and little affinity for δOR (Ki=53 and 1,200 nM, respectively).It is for research use only, and the end user must be the universities.

​​GS-1427​​ is a drug candidate specifically designed based on this mechanism. It potently inhibits the α4β7–MAdCAM-1 interaction with picomolar-level activity while demonstrating high selectivity.

Fraisinib is a specific and effective inhibitor of glycyl-tRNA synthetase 1 (GARS1), suppresses the synthesis of Ap4A by GARS1 and displays strong anti-tumoral potential.

SPI-21 (Spt5-Pol II inhibitor 21) is a small-molecule inhibitor of Spt5-Pol II with IC50 of 25.2 uM.

This study investigates neuroblastoma with additional insights into medulloblastoma, revealing that the small-molecule compound FLIX5 exhibits broad-spectrum cytotoxicity against both tumor types, primarily by inducing apoptosis. Under conditions of impaired mitochondrial function, FLIX5 was found to enhance cholesterol dependency in neuroblastoma cells. Furthermore, FLIX5 demonstrated synergistic anticancer effects when combined with the conventional chemotherapeutic agent vincristine in both cellular and organoid models. Using techniques including protein solubility profiling, molecular docking predictions, and cellular thermal shift assays, the study identified EPLIN (Epithelial Protein Lost In Neoplasm)—a previously unexplored drug target—as the binding target of FLIX5. EPLIN is involved in multiple cellular processes such as cholesterol uptake and mitochondrial function. These findings offer a novel therapeutic target and strategy for treating aggressive pediatric cancers with MYCN amplification, with potential implications for eradicating drug-resistant dormant tumor cells and expanding treatment indications.